Dianthus Therapeutics announces equity inducement grants under Nasdaq Rule 5635(c)(4)
Dianthus Therapeutics said it granted equity awards as inducements under Nasdaq Listing Rule 5635(c)(4).
NEW YORK and WALTHAM, Mass., Sept.
02, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc.
NASDAQ:DNTH, a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced that it granted equity awards o…